LISCure Biosciences Revenue

About LISCure Biosciences

The human microbiome has never been so emphasized. There are some well-known scientific discoveries associated with the human microbiome. i) 95% of bacteria live in the gut, which has a high correlation with metabolic diseases ii) 70% of the immune system is housed in the gut, which has a high correlation with cancer and immune diseases iii) central nervous system is connected to the gut, which has a high correlation with CNS. LISCure is the only company that covers all of its indications based on recent scientific discoveries. LISCure is a clinical-stage biotherapeutic company focused on developing bacteria-mediated immunotherapy using a single strain approach for major therapeutic areas. The company focuses on two therapeutic modalities. 1) Bacteria-mediated Immunotherapy, which is oncology focus injectable therapeutics achieving complete remission with a single dose as monotherapy in our animal models. 2) Microbiome Therapeutics, which is conventional microbiome therapeutics but novel indications such as metabolic diseases, autoimmune diseases, CNS, etc. LISCure has over 10 different drug candidates selected through its own LMT platform technology, which is composed of therapeutic screening, microbial optimization, and microbiome database. There are currently two candidates, LB-P6 and LB-P8, under clinical trial phase 1, and two other candidates, LB-P2D and P4, are expected to enter clinical trial this year. For more information, please visit http://www.liscure.bio/eng/main/ .

View contact profiles from LISCure Biosciences